388 related articles for article (PubMed ID: 17552110)
1. Intermediate vancomycin susceptibility in a community-associated MRSA clone.
Graber CJ; Wong MK; Carleton HA; Perdreau-Remington F; Haller BL; Chambers HF
Emerg Infect Dis; 2007 Mar; 13(3):491-3. PubMed ID: 17552110
[TBL] [Abstract][Full Text] [Related]
2. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
3. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
Kelley PG; Gao W; Ward PB; Howden BP
J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
Rouse MS; Piper KE; Jacobson M; Jacofsky DJ; Steckelberg JM; Patel R
J Antimicrob Chemother; 2006 Feb; 57(2):301-5. PubMed ID: 16361330
[TBL] [Abstract][Full Text] [Related]
6. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
[TBL] [Abstract][Full Text] [Related]
7. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
[TBL] [Abstract][Full Text] [Related]
8. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
Vikram HR; Havill NL; Koeth LM; Boyce JM
J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
[TBL] [Abstract][Full Text] [Related]
9. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
Mariani PG; Sader HS; Jones RN
J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
[No Abstract] [Full Text] [Related]
10. An analysis of a community-acquired pathogen in a Kentucky community: methicillin-resistant Staphylococcus aureus.
Arnold FW; Wojda B
J Ky Med Assoc; 2005 May; 103(5):206-10. PubMed ID: 15918650
[TBL] [Abstract][Full Text] [Related]
11. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
[TBL] [Abstract][Full Text] [Related]
12. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
13. Healthy children with invasive community-acquired methicillin-resistant Staphylococcus aureus infections.
Stankovic C; Mahajan PV
Pediatr Emerg Care; 2006 May; 22(5):361-3. PubMed ID: 16714967
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Appleman MD; Citron DM
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ahmad NM; Rojtman AD
Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
[TBL] [Abstract][Full Text] [Related]
16. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
17. Two heterogeneously vancomycin-intermediate clinical isolates of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in a Turkish university hospital: brief report of a surveillance study.
Torun MM; Bahar H; Demirci M; Altaş K; Bağdatli Y; Kocazeybek B; Kapi M; Hiramatsu K
Int J Antimicrob Agents; 2005 Dec; 26(6):508-10. PubMed ID: 16256313
[No Abstract] [Full Text] [Related]
18. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
Skiest DJ
J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Mangili A; Bica I; Snydman DR; Hamer DH
Clin Infect Dis; 2005 Apr; 40(7):1058-60. PubMed ID: 15825002
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial resistance in clinical isolates of Staphylococcus aureus from hospital and community sources in southern Jamaica.
Brown PD; Ngeno C
Int J Infect Dis; 2007 May; 11(3):220-5. PubMed ID: 16815064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
